| Catalog No. | HW412016 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG4-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | C-C CKR-5, CC-CKR-5, CMKBR5, HIV-1 fusion coreceptor, CHEMR13, CCR5, C-C chemokine receptor type 5, CD195, CCR-5 |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | P51681 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | HuPRO-140, PA-14, PRO-140, 674782-26-4 |
|---|
| Background | Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer.
• Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19., PMID:34530915
• CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells., PMID:25840792
• Retinopathy severity correlates with RANTES concentrations and CCR 5-positive microvesicles in diabetes., PMID:31891363
• Effects of conventional CPB and mini-CPB on neutrophils CD162, CD166 and CD195 expression., PMID:27625334
• Acute response of peripheral CCr5 chemoreceptor and NK cells in individuals submitted to a single session of low-intensity strength exercise with blood flow restriction., PMID:25643617
• Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy., PMID:27781132
|
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
